Astra ditches a Duo
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
CSPC looks for HER2 white space
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Datroway and Trodelvy's new breast cancer battle
But the Astra/Daiichi ADC stumbles in lung cancer.
Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
ASCO-GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
The month ahead: January’s remaining events
JP Morgan approaches.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Enhertu completes its front-line march
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
SABCS 2025 – Gilead hasn’t given up on its Ascent
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
